$MIRM
Mirum Pharmaceuticals, Inc.

2023 Q3 Form 10-Q Financial Statement

#000095017023038716 Filed on August 07, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2
Revenue $47.73M $37.50M
YoY Change 154.13% 114.46%
Cost Of Revenue $10.23M $6.812M
YoY Change 248.91% 169.89%
Gross Profit $37.50M $30.69M
YoY Change 136.62% 105.11%
Gross Profit Margin 78.58% 81.83%
Selling, General & Admin $36.53M $32.95M
YoY Change 62.25% 57.13%
% of Gross Profit 97.41% 107.38%
Research & Development $26.12M $22.01M
YoY Change -0.38% -13.46%
% of Gross Profit 69.65% 71.73%
Depreciation & Amortization $2.670M $1.336M
YoY Change 143.61% 123.04%
% of Gross Profit 7.12% 4.35%
Operating Expenses $72.87M $61.77M
YoY Change 41.06% 26.25%
Operating Profit -$25.15M -$24.27M
YoY Change -23.52% -22.8%
Interest Expense $490.0K -$99.00K
YoY Change -118.71% -97.04%
% of Operating Profit
Other Income/Expense, Net $1.322M -$274.0K
YoY Change -788.54% -121.09%
Pretax Income -$23.34M -$73.72M
YoY Change -34.61% 120.12%
Income Tax $249.0K $316.0K
% Of Pretax Income
Net Earnings -$23.59M -$74.04M
YoY Change -33.94% 175.01%
Net Earnings / Revenue -49.42% -197.45%
Basic Earnings Per Share -$0.57 -$1.94
Diluted Earnings Per Share -$0.57 -$1.94
COMMON SHARES
Basic Shares Outstanding 38.30M 38.03M
Diluted Shares Outstanding 41.10M 38.11M

Balance Sheet

Concept 2023 Q3 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $306.0M $330.0M
YoY Change 65.11% 164.06%
Cash & Equivalents $303.1M $297.2M
Short-Term Investments $2.971M $32.73M
Other Short-Term Assets $12.50M $9.729M
YoY Change 80.4% 157.52%
Inventory $22.25M $8.509M
Prepaid Expenses
Receivables $47.83M $35.33M
Other Receivables $0.00 $0.00
Total Short-Term Assets $388.6M $383.5M
YoY Change 80.27% 160.46%
LONG-TERM ASSETS
Property, Plant & Equipment $787.0K $866.0K
YoY Change -1.01% 4.09%
Goodwill
YoY Change
Intangibles $258.3M $56.44M
YoY Change 473.68% 22.5%
Long-Term Investments
YoY Change
Other Assets $1.510M $1.153M
YoY Change -11.7% -33.04%
Total Long-Term Assets $262.1M $60.07M
YoY Change 76.13% -59.95%
TOTAL ASSETS
Total Short-Term Assets $388.6M $383.5M
Total Long-Term Assets $262.1M $60.07M
Total Assets $650.6M $443.6M
YoY Change 78.58% 49.24%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $7.369M $14.45M
YoY Change -30.14% 77.93%
Accrued Expenses $66.21M $42.69M
YoY Change 72.83% 23.61%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $74.66M $58.20M
YoY Change 45.27% 28.84%
LONG-TERM LIABILITIES
Long-Term Debt $306.0M $305.6M
YoY Change
Other Long-Term Liabilities $7.000K $10.00K
YoY Change -99.84% -99.76%
Total Long-Term Liabilities $7.000K $10.00K
YoY Change -99.84% -99.76%
TOTAL LIABILITIES
Total Short-Term Liabilities $74.66M $58.20M
Total Long-Term Liabilities $7.000K $10.00K
Total Liabilities $381.6M $365.0M
YoY Change 95.62% 95.65%
SHAREHOLDERS EQUITY
Retained Earnings -$520.6M -$497.0M
YoY Change 46.07% 54.97%
Common Stock $791.1M $575.5M
YoY Change 50.37% 33.35%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $269.1M $78.61M
YoY Change
Total Liabilities & Shareholders Equity $650.6M $443.6M
YoY Change 78.58% 49.24%

Cashflow Statement

Concept 2023 Q3 2023 Q2
OPERATING ACTIVITIES
Net Income -$23.59M -$74.04M
YoY Change -33.94% 175.01%
Depreciation, Depletion And Amortization $2.670M $1.336M
YoY Change 143.61% 123.04%
Cash From Operating Activities -$18.22M -$2.331M
YoY Change -29.99% -88.44%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $15.07M
YoY Change -100.0% -88735.29%
Acquisitions
YoY Change
Other Investing Activities -$182.8M $50.62M
YoY Change 129.86% 111.0%
Cash From Investing Activities -$182.8M $35.55M
YoY Change 129.8% 48.29%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $305.4M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 207.1M 114.7M
YoY Change 140.66% 2086.56%
NET CHANGE
Cash From Operating Activities -18.22M -2.331M
Cash From Investing Activities -182.8M 35.55M
Cash From Financing Activities 207.1M 114.7M
Net Change In Cash 6.150M 147.9M
YoY Change -131.56% 1535.41%
FREE CASH FLOW
Cash From Operating Activities -$18.22M -$2.331M
Capital Expenditures $0.00 $15.07M
Free Cash Flow -$18.22M -$17.40M
YoY Change -29.94% -13.67%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0001759425
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38981
dei Entity Registrant Name
EntityRegistrantName
Mirum Pharmaceuticals, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
83-1281555
dei Entity Address Address Line1
EntityAddressAddressLine1
950 Tower Lane, Suite 1050,
dei Entity Address City Or Town
EntityAddressCityOrTown
Foster City
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94404
dei City Area Code
CityAreaCode
650
dei Local Phone Number
LocalPhoneNumber
667-4085
dei Security12b Title
Security12bTitle
Common stock, par value $0.0001 per share
dei Trading Symbol
TradingSymbol
MIRM
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
38297975
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
297228000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
28003000
CY2023Q2 us-gaap Short Term Investments
ShortTermInvestments
32726000
CY2022Q4 us-gaap Short Term Investments
ShortTermInvestments
123716000
CY2023Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
35326000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
23994000
CY2023Q2 us-gaap Inventory Net
InventoryNet
8509000
CY2022Q4 us-gaap Inventory Net
InventoryNet
5565000
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
9729000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8947000
CY2023Q2 us-gaap Assets Current
AssetsCurrent
383518000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
190225000
CY2023Q2 us-gaap Restricted Cash Equivalents
RestrictedCashEquivalents
0
CY2022Q4 us-gaap Restricted Cash Equivalents
RestrictedCashEquivalents
100000000
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
866000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
914000
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1614000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1431000
CY2023Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
56437000
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
58954000
CY2023Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1153000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1382000
CY2023Q2 us-gaap Assets
Assets
443588000
CY2022Q4 us-gaap Assets
Assets
352906000
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
14446000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
8690000
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
42693000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
54018000
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1064000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
931000
CY2023Q2 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
0
CY2022Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
1090000
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
58203000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
64729000
CY2023Q2 mirm Revenue Interest Liability Noncurrent
RevenueInterestLiabilityNoncurrent
0
CY2022Q4 mirm Revenue Interest Liability Noncurrent
RevenueInterestLiabilityNoncurrent
140351000
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1154000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1257000
CY2023Q2 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
305611000
CY2022Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
0
CY2023Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
10000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
4532000
CY2023Q2 us-gaap Liabilities
Liabilities
364978000
CY2022Q4 us-gaap Liabilities
Liabilities
210869000
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q2 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
38222058
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
38222058
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
36956345
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
36956345
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
4000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
4000
CY2023Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
575522000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
535074000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-496992000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-392824000
CY2023Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
76000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-217000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
78610000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
142037000
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
443588000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
352906000
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
37497000
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
17484000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
69095000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
30376000
CY2023Q2 mirm Cost Of Sales1
CostOfSales1
6812000
CY2022Q2 mirm Cost Of Sales1
CostOfSales1
2524000
mirm Cost Of Sales1
CostOfSales1
11791000
mirm Cost Of Sales1
CostOfSales1
4948000
CY2023Q2 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
22009000
CY2022Q2 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
25432000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
45557000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
49520000
CY2023Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
32949000
CY2022Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
20969000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
63168000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
40085000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
61770000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
48925000
us-gaap Operating Expenses
OperatingExpenses
120516000
us-gaap Operating Expenses
OperatingExpenses
94553000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-24273000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-31441000
us-gaap Operating Income Loss
OperatingIncomeLoss
-51421000
us-gaap Operating Income Loss
OperatingIncomeLoss
-64177000
CY2023Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
3627000
CY2022Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
293000
us-gaap Investment Income Interest
InvestmentIncomeInterest
5899000
us-gaap Investment Income Interest
InvestmentIncomeInterest
362000
CY2023Q2 mirm Other Nonoperating Interest Expense
OtherNonoperatingInterestExpense
3726000
CY2022Q2 mirm Other Nonoperating Interest Expense
OtherNonoperatingInterestExpense
3875000
mirm Other Nonoperating Interest Expense
OtherNonoperatingInterestExpense
7968000
mirm Other Nonoperating Interest Expense
OtherNonoperatingInterestExpense
7649000
CY2023Q2 us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Issues
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues
0
CY2022Q2 us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Issues
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues
-232000
us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Issues
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues
0
us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Issues
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues
-232000
CY2023Q2 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-49076000
CY2022Q2 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-49076000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-274000
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1299000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1085000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1145000
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-73722000
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-33492000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-103651000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-70087000
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
316000
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-6570000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
517000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-6559000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-74038000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-26922000
us-gaap Net Income Loss
NetIncomeLoss
-104168000
us-gaap Net Income Loss
NetIncomeLoss
-63528000
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.94
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.94
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.84
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.84
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.75
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.75
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.00
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.00
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
38107334
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
32164174
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
941000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37892513
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
31732596
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
38107334
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
32179171
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37892513
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
31740136
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-74038000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-26922000
us-gaap Net Income Loss
NetIncomeLoss
-104168000
us-gaap Net Income Loss
NetIncomeLoss
-63528000
CY2023Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
54000
CY2022Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-22000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
219000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-115000
CY2023Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-114000
CY2022Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-49000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
74000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-52000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-74098000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-26993000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-103875000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-63695000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
142037000
CY2023Q1 mirm Stock Issued During Period Value Contingent Milestone Achievement
StockIssuedDuringPeriodValueContingentMilestoneAchievement
4292000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8728000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-30130000
CY2023Q1 us-gaap Other Comprehensive Income Loss Before Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
353000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
141150000
CY2023Q2 mirm Stock Issued During Period Value Indemnification Holdback Liability
StockIssuedDuringPeriodValueIndemnificationHoldbackLiability
896000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8565000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-74038000
CY2023Q2 us-gaap Other Comprehensive Income Loss Before Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
-60000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
78610000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
120212000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6561000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-36606000
CY2022Q1 us-gaap Other Comprehensive Income Loss Before Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
-96000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
108932000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6818000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-26922000
CY2022Q2 us-gaap Other Comprehensive Income Loss Before Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
-71000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
110687000
us-gaap Profit Loss
ProfitLoss
-104168000
us-gaap Profit Loss
ProfitLoss
-63528000
us-gaap Share Based Compensation
ShareBasedCompensation
16918000
us-gaap Share Based Compensation
ShareBasedCompensation
13379000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2673000
mirm Repayment Of Revenue Interest
RepaymentOfRevenueInterest
-195577000
mirm Repayment Of Revenue Interest
RepaymentOfRevenueInterest
-1856000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
127694000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
23350000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
74000
mirm Non Cash Lease Expense
NonCashLeaseExpense
290000
mirm Non Cash Lease Expense
NonCashLeaseExpense
207000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
1462000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
103000
mirm Non Cash Interest Expense On Revenue Interest Purchase Agreement
NonCashInterestExpenseOnRevenueInterestPurchaseAgreement
5060000
mirm Non Cash Interest Expense On Revenue Interest Purchase Agreement
NonCashInterestExpenseOnRevenueInterestPurchaseAgreement
7649000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
307000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Purchases Sales Issuances Settlements
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Purchases Sales Issuances Settlements
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements
232000
mirm Change In Fair Value Of Contingent Liabilities Associated With Acquisition
ChangeInFairValueOfContingentLiabilitiesAssociatedWithAcquisition
-667000
mirm Change In Fair Value Of Contingent Liabilities Associated With Acquisition
ChangeInFairValueOfContingentLiabilitiesAssociatedWithAcquisition
1299000
mirm Inventory Reserves Under Operating Activity
InventoryReservesUnderOperatingActivity
665000
mirm Inventory Reserves Under Operating Activity
InventoryReservesUnderOperatingActivity
0
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-49076000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
mirm Tax Benefit Associated With An Acquisition
TaxBenefitAssociatedWithAnAcquisition
0
mirm Tax Benefit Associated With An Acquisition
TaxBenefitAssociatedWithAnAcquisition
6580000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
11332000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
10723000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
782000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1493000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1767000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1247000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-229000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
272000
mirm Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities
IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities
7964000
mirm Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities
IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities
819000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-443000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-345000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-36105000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-59841000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
27329000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
14812000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
120000000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
75300000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
109000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
17000
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
15000000
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
0
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
77562000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
60471000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
14480000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
21289000
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
305304000
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
0
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
3487000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
3917000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-52000
CY2023Q2 us-gaap Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
33779000
CY2023Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
56437000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
169225000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
23928000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
128003000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
131340000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
297228000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
155268000
us-gaap Operating Lease Payments
OperatingLeasePayments
527000
us-gaap Operating Lease Payments
OperatingLeasePayments
438000
mirm Inventory Purchases In Accrued Liabilities
InventoryPurchasesInAccruedLiabilities
1467000
mirm Inventory Purchases In Accrued Liabilities
InventoryPurchasesInAccruedLiabilities
1764000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
473000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
mirm Stock Based Compensation Capitalized To Inventory
StockBasedCompensationCapitalizedToInventory
375000
mirm Stock Based Compensation Capitalized To Inventory
StockBasedCompensationCapitalizedToInventory
177000
mirm Reclassification Of Contingent Milestone Liability To Equity In Connection With Issuance Of Common Stock Upon Achievement Of Contingent Milestone
ReclassificationOfContingentMilestoneLiabilityToEquityInConnectionWithIssuanceOfCommonStockUponAchievementOfContingentMilestone
4292000
mirm Reclassification Of Contingent Milestone Liability To Equity In Connection With Issuance Of Common Stock Upon Achievement Of Contingent Milestone
ReclassificationOfContingentMilestoneLiabilityToEquityInConnectionWithIssuanceOfCommonStockUponAchievementOfContingentMilestone
0
mirm Indemnification Holdback Liability Connection With Settlement
IndemnificationHoldbackLiabilityConnectionWithSettlement
896000
mirm Indemnification Holdback Liability Connection With Settlement
IndemnificationHoldbackLiabilityConnectionWithSettlement
0
mirm Issuance Of Common Stock In Exchange For Acquired Intangible Assets
IssuanceOfCommonStockInExchangeForAcquiredIntangibleAssets
0
mirm Issuance Of Common Stock In Exchange For Acquired Intangible Assets
IssuanceOfCommonStockInExchangeForAcquiredIntangibleAssets
15585000
mirm Contingent Milestone Liability For Common Stock Issuance For Acquired Intangible Assets
ContingentMilestoneLiabilityForCommonStockIssuanceForAcquiredIntangibleAssets
0
mirm Contingent Milestone Liability For Common Stock Issuance For Acquired Intangible Assets
ContingentMilestoneLiabilityForCommonStockIssuanceForAcquiredIntangibleAssets
4600000
mirm Indemnification Holdback Liability In Exchange For Acquired Intangible Assets
IndemnificationHoldbackLiabilityInExchangeForAcquiredIntangibleAssets
0
mirm Indemnification Holdback Liability In Exchange For Acquired Intangible Assets
IndemnificationHoldbackLiabilityInExchangeForAcquiredIntangibleAssets
831000
mirm Transaction Costs From Acquisition In Accrued Liabilities
TransactionCostsFromAcquisitionInAccruedLiabilities
0
mirm Transaction Costs From Acquisition In Accrued Liabilities
TransactionCostsFromAcquisitionInAccruedLiabilities
176000
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2018-05-02
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-497000000.0
CY2023Q2 mirm Cash Cash Equivalents And Short And Long Term Investments
CashCashEquivalentsAndShortAndLongTermInvestments
330000000.0
CY2023Q2 mirm Unrestricted Cash Cash Equivalents And Short And Long Term Investments
UnrestrictedCashCashEquivalentsAndShortAndLongTermInvestments
330000000.0
CY2023Q2 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
305300000
CY2023Q2 mirm Proceeds To Repurchase Future Revenue Interests
ProceedsToRepurchaseFutureRevenueInterests
192700000
CY2023Q2 us-gaap Restricted Cash Equivalents
RestrictedCashEquivalents
100000000.0
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of consolidated financial statements in accordance with GAAP requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">in the financial statements and accompanying notes. These estimates and assumptions are based upon historical experience, knowledge of current events and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results could differ materially from those estimates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company’s unaudited condensed consolidated financial statements as of and for the three and six months ended June 30, 2023 reflect the Company’s estimates of the impact of the geopolitical and macroeconomic environment, including the impact of inflation, bank failures, higher interest rates and foreign exchange rate fluctuations. The duration and the scope of these conditions cannot be predicted; therefore, the extent to which these conditions will directly or indirectly impact the Company’s business, results of operations and financial condition, is uncertain. The Company is not aware of any specific event or circumstance that would require an update to its estimates, judgments and assumptions or a revision of the carrying value of the Company’s assets or liabilities as of the date of this filing.</span></p>
CY2022Q4 us-gaap Restricted Cash Equivalents
RestrictedCashEquivalents
100000000.0
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
297228000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
28003000
CY2023Q2 us-gaap Restricted Cash Equivalents
RestrictedCashEquivalents
0
CY2022Q4 us-gaap Restricted Cash Equivalents
RestrictedCashEquivalents
100000000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
297228000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
128003000
mirm Investments Classified As Cash And Cash Equivalent Original Maturities
InvestmentsClassifiedAsCashAndCashEquivalentOriginalMaturities
P3M
mirm Fair Value Of Its Investments Related To Credit Loss
FairValueOfItsInvestmentsRelatedToCreditLoss
0
CY2023Q2 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0
CY2023Q2 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
0
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
0
CY2022Q2 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
0
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
0
CY2023Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
62107000
CY2023Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
5670000
CY2023Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
56437000
CY2022Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
62107000
CY2022Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
3153000
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
58954000
us-gaap Acquired Finite Lived Intangible Assets Weighted Average Useful Life
AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
P12Y9M18D
CY2023Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1300000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2500000
CY2022Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
500000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
800000
CY2023Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
2518000
CY2023Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
5035000
CY2023Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
5035000
CY2023Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
5035000
CY2023Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
5035000
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-26922000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-63528000
CY2022Q2 mirm Fair Value Adjustment Of Holdback Indemnification Liability
FairValueAdjustmentOfHoldbackIndemnificationLiability
199000
mirm Fair Value Adjustment Of Holdback Indemnification Liability
FairValueAdjustmentOfHoldbackIndemnificationLiability
199000
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-27121000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-63727000
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
32164174
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
31732596
CY2022Q2 mirm Weighted Average Holdback Indemnification Shares Issuable
WeightedAverageHoldbackIndemnificationSharesIssuable
14997
mirm Weighted Average Holdback Indemnification Shares Issuable
WeightedAverageHoldbackIndemnificationSharesIssuable
7540
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
32179171
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
31740136
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.84
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.00
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.84
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.00
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
20634345
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9179001
CY2022Q2 mirm Available For Sale Securities Gross Realized Gain Loss Net1
AvailableForSaleSecuritiesGrossRealizedGainLossNet1
0
mirm Available For Sale Securities Gross Realized Gain Loss Net1
AvailableForSaleSecuritiesGrossRealizedGainLossNet1
0
CY2023Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
0
CY2022Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
0
CY2023Q2 mirm Cash Equivalents And Available For Sale Debt Securities Amortized Cost Basis
CashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis
317740000
CY2023Q2 mirm Cash Equivalents And Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0
CY2023Q2 mirm Cash Equivalents And Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
12000
CY2023Q2 mirm Cash Equivalents And Available For Sale Securities Debt Securities
CashEquivalentsAndAvailableForSaleSecuritiesDebtSecurities
317728000
CY2023Q2 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
285002000
CY2023Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
32726000
CY2023Q2 mirm Cash Equivalents And Available For Sale Securities Debt Securities
CashEquivalentsAndAvailableForSaleSecuritiesDebtSecurities
317728000
CY2022Q4 mirm Cash Equivalents And Available For Sale Debt Securities Amortized Cost Basis
CashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis
248172000
CY2022Q4 mirm Cash Equivalents And Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0
CY2022Q4 mirm Cash Equivalents And Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
230000
CY2022Q4 mirm Cash Equivalents And Available For Sale Securities Debt Securities
CashEquivalentsAndAvailableForSaleSecuritiesDebtSecurities
247942000
CY2022Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
24226000
CY2022Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
100000000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
123716000
CY2022Q4 mirm Cash Equivalents And Available For Sale Securities Debt Securities
CashEquivalentsAndAvailableForSaleSecuritiesDebtSecurities
247942000
CY2023Q2 mirm Available For Sale Securities Gross Realized Gain Loss Net1
AvailableForSaleSecuritiesGrossRealizedGainLossNet1
0
mirm Available For Sale Securities Gross Realized Gain Loss Net1
AvailableForSaleSecuritiesGrossRealizedGainLossNet1
0
us-gaap Other Than Temporary Impairment Loss Debt Securities Available For Sale
OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
0
us-gaap Other Than Temporary Impairment Loss Debt Securities Available For Sale
OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
0
CY2023Q2 us-gaap Inventory Work In Process
InventoryWorkInProcess
6965000
CY2022Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
5351000
CY2023Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
1544000
CY2022Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
214000
CY2023Q2 us-gaap Inventory Net
InventoryNet
8509000
CY2022Q4 us-gaap Inventory Net
InventoryNet
5565000
CY2023Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
10957000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
14660000
CY2023Q2 mirm Accrued Rebates Payable Current
AccruedRebatesPayableCurrent
7385000
CY2022Q4 mirm Accrued Rebates Payable Current
AccruedRebatesPayableCurrent
4284000
CY2023Q2 mirm Accrued Clinical Trials Current
AccruedClinicalTrialsCurrent
6599000
CY2022Q4 mirm Accrued Clinical Trials Current
AccruedClinicalTrialsCurrent
8319000
CY2023Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
6584000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
5372000
CY2023Q2 mirm Accrued Contract Manufacturing And Non Clinical Costs Current
AccruedContractManufacturingAndNonClinicalCostsCurrent
5665000
CY2022Q4 mirm Accrued Contract Manufacturing And Non Clinical Costs Current
AccruedContractManufacturingAndNonClinicalCostsCurrent
3927000
CY2023Q2 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
2902000
CY2022Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
2456000
CY2023Q2 us-gaap Interest Payable Current
InterestPayableCurrent
2601000
CY2022Q4 us-gaap Interest Payable Current
InterestPayableCurrent
0
CY2023Q2 mirm Accrued Milestone Payments Current
AccruedMilestonePaymentsCurrent
0
CY2022Q4 mirm Accrued Milestone Payments Current
AccruedMilestonePaymentsCurrent
15000000
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
42693000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
54018000
CY2022Q4 mirm Revenue Interest Liability
RevenueInterestLiability
140351000
CY2022Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
1090000
CY2023Q1 mirm Interest Expense Accrued
InterestExpenseAccrued
4242000
CY2023Q1 mirm Derivative Liability Accrued
DerivativeLiabilityAccrued
0
CY2023Q1 mirm Revenue Interest Payments
RevenueInterestPayments
-2883000
CY2023Q1 mirm Derivative Liability Payments
DerivativeLiabilityPayments
0
CY2023Q1 mirm Revenue Interest Liability
RevenueInterestLiability
141710000
CY2023Q1 us-gaap Derivative Liabilities
DerivativeLiabilities
1090000
CY2023Q2 mirm Interest Expense Accrued
InterestExpenseAccrued
818000
CY2023Q2 mirm Derivative Liability Accrued
DerivativeLiabilityAccrued
0
CY2023Q2 mirm Revenue Interest Liability Settlement
RevenueInterestLiabilitySettlement
-192694000
CY2023Q2 mirm Derivative Liability Settlement
DerivativeLiabilitySettlement
0
CY2023Q2 mirm Gains Losses On Extinguishment Of Debt Revenue Interest Liability
GainsLossesOnExtinguishmentOfDebtRevenueInterestLiability
50166000
CY2023Q2 mirm Gains Losses On Extinguishment Of Derivative Liability
GainsLossesOnExtinguishmentOfDerivativeLiability
-1090000
CY2023Q2 mirm Revenue Interest Liability
RevenueInterestLiability
0
CY2023Q2 us-gaap Derivative Liabilities
DerivativeLiabilities
0
mirm Stock Issued During Period Shares Indemnification Holdback Liability
StockIssuedDuringPeriodSharesIndemnificationHoldbackLiability
31631
CY2019Q1 us-gaap Area Of Land
AreaOfLand
5600
us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
The lease term is approximately four years with an option to extend the term for one five-year term, which at the time was not reasonably assured of exercise and therefore, not included in the lease term.
CY2019Q1 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P4Y
CY2019Q1 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P5Y
CY2019Q1 mirm Tenant Improvement Allowance
TenantImprovementAllowance
400000
CY2023Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.080
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1600000
CY2023Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
2200000
CY2023Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y4M24D
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
599000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1191000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
357000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
114000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
114000
CY2023Q2 mirm Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
57000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
2432000
CY2023Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
214000
CY2023Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
2218000
CY2023Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
200000
CY2022Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
200000
us-gaap Operating Lease Expense
OperatingLeaseExpense
400000
us-gaap Operating Lease Expense
OperatingLeaseExpense
400000
CY2020Q3 mirm Maximum Amount Of Sale Covered In Shelf Registration Statement
MaximumAmountOfSaleCoveredInShelfRegistrationStatement
300000000.0
CY2023Q2 mirm Common Stock Aggregate Offering Price Remaining
CommonStockAggregateOfferingPriceRemaining
31300000
CY2023Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
23146255
CY2022Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
11941705
CY2022Q2 us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
200000
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8357000
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6641000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
16918000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
13202000
CY2023Q2 us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
200000
us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
400000
us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
200000

Files In Submission

Name View Source Status
0000950170-23-038716-index-headers.html Edgar Link pending
0000950170-23-038716-index.html Edgar Link pending
0000950170-23-038716.txt Edgar Link pending
0000950170-23-038716-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
mirm-20230630.htm Edgar Link pending
mirm-20230630.xsd Edgar Link pending
mirm-ex10_1.htm Edgar Link pending
mirm-ex31_1.htm Edgar Link pending
mirm-ex32_1.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
mirm-20230630_cal.xml Edgar Link unprocessable
mirm-20230630_def.xml Edgar Link unprocessable
mirm-20230630_lab.xml Edgar Link unprocessable
mirm-20230630_pre.xml Edgar Link unprocessable
mirm-20230630_htm.xml Edgar Link completed
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending